NCT06764017View on ClinicalTrials.gov

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

August 1, 2027

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

CHiR-DEL

Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.

Trial Locations (1)

3150101

RECRUITING

The First Affiliated Hospital of Ningbo University, Ningbo

All Listed Sponsors
lead

First Affiliated Hospital of Ningbo University

NETWORK